Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02877056|
Recruitment Status : Recruiting
First Posted : August 24, 2016
Last Update Posted : May 29, 2019
The goal of this laboratory research is to look for genes that can predict which patients will achieve a complete disappearance of their colorectal cancer after treatment like chemotherapy, radiation, or other therapy.
This is an investigational study. Up to 350 patients will take part in this study. All will be enrolled at MD Anderson.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Procedure: Endoscopy|
Patients with colorectal cancer usually receive radiation, chemotherapy, or other therapy before they have surgery. At this time, there are no tests that can help researchers find out which patients no longer have any tumor left after completing treatment. Because of this, all patients have to have surgery to completely remove the rectum and/or part of the colon. This procedure results in lifestyle changes for the patient, which may be difficult and permanent.
Researchers are looking for new ways to find out which patients will have no tumor left after treatment, so that in the future, some patients may be able to avoid surgery altogether. In this study, researchers will try to use chemical "markers" in tumor cells as a way to possibly predict whether or not the tumor is likely to disappear with treatment alone.
At MD Anderson, all patients with colorectal cancer have an endoscopy performed by their surgeon as part of standard care, before they start therapy. Endoscopy involves placing a narrow tube in the colon and/or rectum in order to see and inspect the tumor.
If you choose to take part in this study, tissue samples will be taken from the tumor and the normal areas during your standard endoscopy. If you undergo surgery, tissue samples from the tumor(s) and normal areas will also be collected. At the time of endoscopy and/or surgery, once the doctor has finished all standard tests on this tissue and has received the clinical reports on these tests, any leftover tissue samples will be collected by Dr. You or a person on her research team for research tests to look for tumor cell "markers." Researchers want to find out how these markers may have changed since you began receiving treatment for the disease.
Some of the tissue from your biopsies may also be sent to the labs at University of Texas-Southwest or Natera for testing. No identifying information about you will be included with these samples. They will have a special number assigned, so that the samples being sent to UT Southwest or Natera will not be able to be connected to you in any way.
The results of these tests will not be used to make any decisions regarding treatment of your rectal cancer. There are no other tests or procedures required in this study
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer|
|Actual Study Start Date :||August 2005|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||August 2023|
Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
- Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer [ Time Frame: 1 day ]Tissue taken at endoscopy undergoes testing for tumor cell biomarkers to identify patients who achieve complete response (CR).
Biospecimen Retention: Samples With DNA
Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy.
Up to eight biopsy samples of the tumor as well as up to six biopsies of the grossly normal colorectum obtained.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02877056
|Contact: Yi-Qian N. You, MD||713-792-6940||YNYou@mdanderson.org|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Yi-Qian N. You, MD||M.D. Anderson Cancer Center|